PDF(Pubmed)
Abstract：
Preclinical cases suggest that EGFR tyrosine kinase inhibitors (TKIs) plus MET TKIs are a potential therapy for non-classical EGFR mutant lung cancers with MET amplification acquired resistance. Herein, we report for the first time the effectiveness of novel combination treatment regimens for patients with EGFR G719X/S768I/L861Q. Until the last follow-up assessment, two patients demonstrated improved survival after they switched to afatinib combined with savolitinib (PFS: 10 months) and furmonertinib combined with crizotinib (PFS: 6 months), respectively, that did not observed increased incidence and severity of adverse events. According to the findings of this study and literature review, various responses were observed from the combined therapy in NSCLC patients who harbored uncommon EGFR mutations and MET amplification. Furthermore, Next generation sequencing (NGS) leads to the discovery of uncommon of EGFR and reveals the co-mutations in NSCLC.
摘要：
临床前病例表明，EGFR酪氨酸激酶抑制剂（TKIs）加METTKIs是治疗具有MET扩增获得性耐药的非经典EGFR突变肺癌的潜在疗法。在这里，我们首次报道了EGFRG719X/S768I/L861Q患者新型联合治疗方案的有效性.直到最后一次后续评估，两名患者在改用阿法替尼联合萨沃利替尼（PFS：10个月）和呋喃替尼联合克唑替尼（PFS：6个月）后，生存率得到改善，分别,未观察到不良事件的发生率和严重程度增加。根据本研究的结果和文献综述，在EGFR突变和MET扩增不常见的NSCLC患者中,观察到联合治疗的各种缓解.此外，下一代测序(NGS)导致发现不常见的EGFR,并揭示NSCLC中的共突变。
